Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: An NRG Oncology Group study

INTRODUCTION: To describe patient-reported outcomes and toxicities at time of treatment discontinuation secondary to progression or toxicities in advanced/recurrent cervical cancer patients receiving chemotherapy with bevacizumab. METHODS: Summarize toxicity, grade, and health-related quality of lif...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Gynecol Cancer
Autors principals: Chase, D.M., Huang, H.Q., Monk, B.J., Ramondetta, L.M., Penson, R.T., Gil, K., Landrum, L.M., Leitao, M.M., Oaknin, A., Huh, W.K., Pulaski, H.L., Robison, K., Guntupalli, S.R., Richardson, D., Salani, R., Sill, M.W., Wenzel, L.B., Tewari, K.S.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7780262/
https://ncbi.nlm.nih.gov/pubmed/32114513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ijgc-2019-000869
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars